Canada: Pharmacapsules @ Gowlings - April 14, 2011

Last Updated: April 19 2011

Edited by Jennifer Wilkie and Isabel Raasch

In this issue:

  • Two Amendments to Pharma Legislation Come into Force

  • Other News Items of Interest to the Pharma Community

  • Recent Cases

  • Upcoming Trials, Judicial Reviews and Appeals of Interest


The Amendments to The Food and Drug Regulations (1319- New Drugs For Extraordinary Use) came into force on March 25, 2011. These amendments affect the regulations regarding the design of appropriate clinical trials for a small number of emergency-use drugs, such as anthrax and pandemic influenza vaccines (collectively referred to as Extraordinary Use New Drugs or "EUND"). The Amendment creates a new type of drug submission for EUND within the Regulations and outlines the requirements for EUND submissions, labeling, plans for post-market safety and efficacy data acquisition, and annual reporting. Existing regulations that apply to other drugs such as data and patent protection apply to EUNDs as well. Because of the nature and intended purpose of EUNDs, manufacturers are only permitted to sell them to federal, provincial, territorial or municipal governments.

The full text of the EUND Amendments can be found at:
Regulations Amending the Food and Drug Regulations.pdf

The new Fees in Respect of Drugs and Medical Devices Regulations came into force on April 1, 2011. These new fees constitute an update and consolidation of the various user fees regulations. Key elements of the new fees regulations include (1) establishing fees for regulatory activities (e.g., submission and examination of NDSs and SNDSs, dealer licenses and medical device licenses) and stipulating their amounts in a schedule; (2) establishing timing and allotment of fees payable; (3) providing fee mitigation measures; and (4) providing for an annual adjustment of fees. The fees are designed to lessen the increasing funding pressures on Heath Canada.

The full text of the new fees regulations (including the fee tables) can be found at:
Fees in Respect of Drugs and Medical Devices Regulations.pdf



Apotex Inc. v. Minister of Health (2011 FCA 86) Apo-ASA, March 8, 2011
Appeal of NOC decision

The Court of Appeal upheld a decision dismissing Apotex' application for judicial review of a Minister of Health decision refusing to issue a NOC for Apotex enteric-coated ASA. In particular Apotex had tried to argue to the Minister that certain data in its "fed" bioavailability study were mere outliers and should be disregarded. The Court of Appeal agreed with the Minister that all of Apotex' arguments were based on the incorrect premise that it was open to the Minister to assess the safety and efficacy of Apo-ASA without requiring proof of bioequivalence between Apotex' product and Bayer's product (the Canadian reference product). The Court of Appeal found the applications judge had applied the correct standard of review and stated that given the Minister's finding of no bioequivalence, it was not open to the Minister to grant the NOC on the basis of a comparison with the reference product.

A copy of this decision may be found at the following link:

Phostech Lithium Inc. v. Valance Technology, Inc. (2011 FCA 107) March 18, 2011
Appeal of Stay of Execution

The Federal Court of Appeal granted a stay of execution pending appeal in a patent infringement action. The applicant Appellant (Defendant) had sought the stay. The Court of Appeal recited the 3 part test for granting a stay: (1) is there a serious issue on appeal, (2) will there be irreparable harm, and (3) where does the balance of convenience lie. This test is rarely satisfied, usually failing due to the difficulties of establishing irreparable harm. The Court of Appeal indicated that it was satisfied where there would be irreparable harm to the Appellant by reason of loss of key components to its business (key personnel, scarce suppliers, and customers with tight time requirements). With respect to the balance of convenience, the Court noted that the parties do not compete in the same market so it would only be inconvenient to the Respondent (Plaintiff) and if ultimately the appeal is dismissed, the Plaintiff would be able to obtain a monetary remedy which encompasses the longer time frame. Importantly, the Court did place some conditions/factors in order to grant the stay: (1) a written undertaking as to damages from the Defendant, (2) an additional undertaking not to make distributions to shareholders etc. during the stay period, (3) a bond was deposited with the Court in the amount of $250,000 and (4) the appeal should be expedited.

A copy of this decision may be found at the following link:

Eli Lilly et al. v. Nu-Pharm Inc., (2011 FC 255), olanzapine, T-1548-10, March 3, 2011
Appeal of Order re. motion to strike Statement of Claim

In an action for patent infringement regarding olanzapine, Madam Justice Snider upheld a November 16, 2010 Order of Prothonotary Milczynski striking the Plaintiff's Statement of Claim and awarding costs to Nu-Pharm.

Justice Snider reviewed Prothonotary Milczynski's decision de novo and found that although the Statement of Claim showed facts by virtue of which the law recognizes a defined right as belonging to the Plaintiffs, the pleadings did not disclose a reasonable cause of action. In particular, although the pleadings alleged that Nu-Pharm's actions in obtaining a Notice of Compliance and a Drug Identification Number for its olanzapine product constituted infringement, the pleadings disclosed nothing beyond an assertion that Nu-Pharm was positioning itself (through an unnamed third party) to enter the market. The Court further stated that without something pleaded beyond the regulatory requirements, s. 52.2(1) (i.e., the exemption from infringement solely for the purposes reasonably related to the development and submission of information required for regulatory purposes) of the Patent Act applies.

A copy of this decision may be found at the following link:

Apotex v. Pfizer, 2011 FCA 77, sildenafil, A-371-10, March 1, 2011
Appeal of interlocutory motion in impeachment action

Apotex appealed the finding of the Trial Court which allowed Pfizer's Statement of Defence to include pleadings of issue estoppel, collateral estoppel, comity and abuse of process based on related NOC litigation.

The Court of Appeal reaffirmed that NOC cases are summary in nature and that decisions as to validity or infringement made in an NOC case are not binding in the sense of cause of action estoppel. However, the Court of Appeal noted that depending on the evidence put forward in a subsequent proceeding the doctrines of res judicata and issue estoppel may apply to particular factual and legal findings of the previous application judge's findings. The Court offered the following illustration as an example: if a witness gives exactly the same evidence in both proceedings, and the judge found the witness to be credible in the NOC proceeding, it may be open to the trial judge in the action to bar re-litigation of the witness' credibility through issue estoppel or abuse of process; on the other hand, if the witness gives different or additional evidence at the action, the trial judge may be justified in reconsidering the witness' credibility.

In view of the above, the Court of Appeal found that portions of Pfizer's statement of Defence which contained general statements with regards to litigation bar should be struck, but that other paragraphs relating to specific findings of the previous judge should be allowed.

A copy of this decision may be found at the following link:




Toronto, April 18, 2011 (16 days), Ottawa May 16 (11d)



Toronto, April 18, 2011 (16d), Ottawa May 16 (11d)



Toronto April 26, 27, May 2 (3d)



Montreal, May 2, 2011 (4d)



Toronto, May 9, 2011 (4d)



Ottawa, May 31, 2011 (3d)

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
8 Nov 2016, Seminar, Ottawa, Canada

The prospect of an internal investigation raises many thorny issues. This presentation will canvass some of the potential triggering events, and discuss how to structure an investigation, retain forensic assistance and manage the inevitable ethical issues that will arise.

22 Nov 2016, Seminar, Ottawa, Canada

From the boardroom to the shop floor, effective organizations recognize the value of having a diverse workplace. This presentation will explore effective strategies to promote diversity, defeat bias and encourage a broader community outlook.

7 Dec 2016, Seminar, Ottawa, Canada

Staying local but going global presents its challenges. Gowling WLG lawyers offer an international roundtable on doing business in the U.K., France, Germany, China and Russia. This three-hour session will videoconference in lawyers from around the world to discuss business and intellectual property hurdles.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.